FASN may lead to herceptin resistance in breast cancer through at least two pathways: i) up-regulating PEA3 transcription to inhibit HER2 gene expression, and ii) changing the lipid composition and function of BCC membrane, thereby affecting the membrane localization of HER2.97 This evidence concerns the gene ERBB2 and breast carcinoma.